Distek, Inc. ads

☕ Coffee, Bagels & Benchtop Bioreactors Your time is valuable—and we’re here to make it count. Distek’s Bio-Brunch is an informal, on-site conversation designed around your team, your workflow, and your questions. We’ll bring the coffee and bagels—you bring your curiosity. Whether you're exploring cell culture or microbial fermentation, our BIOne experts will share insights, answer questions, and learn more about the work happening in your lab. 📍 Hosted at your lab. ⏱️ No slides, no pressure—just helpful conversation. 🔗 Schedule Your Bio-Brunch https://lnkd.in/eDtCjm6S 📧 [email protected] | 📞 732.422.7585 #Bioprocessing #CellCulture #Fermentation #BIOne #LabLife #Distek #MadeInUSA #FreeFood #Biotech

The demand for mesenchymal stem cells (hMSCs) continues to rise, but traditional 2D culture systems can’t meet the scale required. Distek’s white paper shows how a single-use, 3D microcarrier-based bioreactor system, achieved 11.9-fold expansion with 96.5% viability in six days, to offer a proven path to scalable, consistent hMSC production.

The demand for pluripotent stem cells (hPSCs) continues to grow, but traditional 2D culture methods can’t deliver the scalability required for modern therapies. Defined Bioscience’s HiDef® S8™ used in a single-use 3D bioreactor, enabled a 60-fold hPSC expansion with >94% viability in just five days, without microcarriers or serum. Discover a simpler, scalable path to high-density hPSC manufacturing.

Scaling hMSC therapies demands more than capacity, it requires innovation. Distek’s white paper introduces a next-generation 3D microcarrier bioreactor system that redefines stem cell expansion, achieving 11.9-fold growth and 96.5% viability in six days. Learn how this platform empowers organizations to scale faster, reduce risk, and accelerate therapeutic development.

Next-generation cell therapies demand next-generation processes. Defined Bioscience’s HiDef® S8™ medium powered 60-fold expansion and >94% viability in five days within Distek’s BIOne bioreactor, reducing cost per million cells to under US$0.30. Learn how this chemically defined, animal-free system transforms 3D suspension workflows into production-ready solutions.

For next-generation biologics, precision control drives performance. Distek and 908 Devices introduce a continuous glucose control strategy that delivers 17% higher CHO productivity and 12% higher IgG titers, all with standard, ready-to-integrate tools. Explore how real-time analytics and automated feeding unlock scalable, data-driven bioprocess optimization.